KRRO Korro Bio, Inc.
Korro Bio, Inc. (KRRO) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $1.25 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +15.5% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Korro Bio, Inc.
Korro Bio Inc. is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and highly prevalent diseases. Korro Bio Inc., formerly known as Frequency Therapeutics Inc., is based in LEXINGTON, Mass.
Sector
Healthcare
Industry
Biotechnology